# A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct02324569` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02324569](<https://clinicaltrials.gov/study/NCT02324569>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02324569

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT02324569. Randomized; quadruple masking; primary purpose treatment. Start 2014-12-27 (actual); primary completion 2016-12-28 (actual). Results posted on 2019-02-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT02324569, source copy `cardio:ctgov-nct02324569-2023-12-12`, retrieved 2026-10-26)
- Started: 2014-12-27 (actual) (ClinicalTrials.gov record NCT02324569, source copy `cardio:ctgov-nct02324569-2023-12-12`, retrieved 2026-10-26)
- Primary completion: 2016-12-28 (actual) (ClinicalTrials.gov record NCT02324569, source copy `cardio:ctgov-nct02324569-2023-12-12`, retrieved 2026-10-26)
- Completion: 2016-12-28 (actual) (ClinicalTrials.gov record NCT02324569, source copy `cardio:ctgov-nct02324569-2023-12-12`, retrieved 2026-10-26)
- Results first posted: 2019-02-11 (ClinicalTrials.gov record NCT02324569, source copy `cardio:ctgov-nct02324569-2023-12-12`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02324569, source copy `cardio:ctgov-nct02324569-2023-12-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02324569-2023-12-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): SYR-472
- Intervention (Drug): Placebo
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 3d470269b248997fcdc2dcd587acee9d58a811f25c5aa0d35f32b10939a0729e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
